Kemin Industries and its subsidiary Kemin Biologics have signed an exclusive agreement with Pacific GeneTech (PGT) to license the latter's TMH001 Eimeria vaccine for poultry.
PGT is a biologics company that develops and commercialises next-generation vaccines for areas of unmet needs in animal health and food safety.
TMH001 is the only inactivated, oral vaccine that contains highly conserved Apicomplexan antigens and the patented Hercules adjuvant that are delivered by a novel, proprietary Pichia yeast vector. As a cross-protective vaccine on the market for Eimeria, it will provide a safe and effective alternative solution to antibiotics and disease-inducing live vaccines.
Tim Collard, PGT's CEO, said: "With its proven commitment to new and sustainable technologies for food security and safety, Kemin was the ideal partner for TMH001. We are thrilled to be working side-by-side with them to bring innovative solutions to market that are needed in the animal health industry."
Kemin Biologics, a division of Kemin Industries that focuses on developing vaccines as the first line of defence against diseases, entered into the partnership with PGT last month. As part of the partnership, Kemin will focus on developing the Eimeria vaccine and registering it in the United States and other countries beginning with the European Union. Kemin will also expand the Eimeria vaccine's availability to Asia, the Middle East, Africa and Latin America.
"Kemin sees great potential in the marketplace for innovative vaccines and is dedicated to improving the health of poultry and livestock which ensures the safety of our global food supply," said Dr. Chris Nelson, president and CEO of Kemin Industries. "This new agreement with Pacific GeneTech continues our advancement in providing next-generation vaccines that have the ability to transform the quality of life around the world."
In addition to a high safety profile, TMH001 provides demonstrable cross protection against five economically important species of Eimeria with the potential to protect against more species. TMH001 was developed from PGT's proprietary Aegis vaccine platform which has produced other cross-protective vaccines that address multiple pathogens. The platform was originally developed by the University of Arkansas's Poultry Health Laboratory in collaboration with other US universities and support from the US Department of Agriculture.
Visit Kemin at: www.kemin.com